title: A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
abstract: Erlotinib is a standard second-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). However, its efficacy for those patients with epidermal growth factor receptor (EGFR) wild-type (WT) tumors is undecided. In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. We found PFS and OS were significantly improved by erlotinib plus nab-paclitaxel. The adverse events were also well tolerable.
authors.affiliation: Department of Radiation Oncology, Shandong Tumor Hospital and Institute , Jinan , China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Chao
authors.initials: C
authors.lastname: Gao
authors.forename: Wei
authors.initials: W
authors.lastname: Qu
authors.forename: Yongsheng
authors.initials: Y
authors.lastname: Gao
authors.forename: Shouhui
authors.initials: S
authors.lastname: Zhu
authors.forename: Shuo
authors.initials: S
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: He
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000418:Albumins / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D018572:Disease-Free Survival; D000069347:Erlotinib Hydrochloride; D005260:Female; D018773:Genes, erbB-1; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D017239:Paclitaxel
keywords: EGFR; Erlotinib; NSCLC; Nab-paclitaxel